AEYE Health Inc.

AEYE Health is an FDA-cleared AI diagnostic platform specializing in autonomous diabetic retinopathy screening from retinal images. The company offers AEYE-DS, the only fully autonomous AI solution for point-of-care diabetic retinopathy detection requiring a single image per eye, enabling primary care physicians, pharmacies, and home care providers to perform rapid screening without specialist referral. AEYE Health also develops AEYE-X, a broader retinal imaging diagnostic platform for detecting multiple eye and systemic diseases. Operating with handheld cameras (Aurora AEYE with Optomed) and robotic tabletop systems (integrated with Topcon Healthcare), the company targets the >40 million Americans with diabetes, achieving 92-93% sensitivity and >99% image success rates. The solution is CPT 92229 reimbursable and addresses critical gaps in diabetic retinopathy care access.